Evidence map›Paper›PMID 41025431›Full record

ArticleCancer biology & medicine2025

Glofitamab

Keshu Zhou, Huijing Wu, Xia Zhao, Xiaohong Tan, Xiaojing Yan, Haisheng Liu, Liping Su, Yukun Lan, Jaihui Xu, Xiaohui Zhou and 2 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biology & medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Keshu ZhouDepartment of Hematology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450003, China.
Huijing WuDepartment of Oncology, Hubei Cancer Hospital, Wuhan 430079, China.
Xia ZhaoDepartment of Lymphoma, The Affiliated Hospital of Qingdao University, Qingdao 266003, China.
Xiaohong TanDepartment of Haematology/Oncology and Paediatric Oncology, Guangxi Medical University Affiliated Cancer Hospital, Nanning 530021, China.
Xiaojing YanDepartment of Hematology, The First Hospital of China Medical University, Shenyang 110001, China.
Haisheng LiuDepartment of Hematology, The Fourth Hospital of Hebei Medical University and Hebei Tumor Hospital, Shijiazhuang 050011, China.
Liping SuDepartment of Hematology, Shanxi Cancer Hospital Institute, Taiyuan 030013, China.
Yukun LanShanghai Roche Pharmaceuticals Ltd., Shanghai 201203, China.
Jaihui XuShanghai Roche Pharmaceuticals Ltd., Shanghai 201203, China.
Xiaohui ZhouShanghai Roche Pharmaceuticals Ltd., Shanghai 201203, China.
Yuerong ShuangDepartment of Lymphatic and Hematological Oncology, Jiangxi Cancer Hospital, Nanchang 330029, China.ORCID 0009-0001-1867-173X
Huilai ZhangDepartment of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China.ORCID 0000-0002-8558-3131

Funding

This study was sponsored by Shanghai Roche Pharmaceuticals Ltd.
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41025431
PMCPMC12533751

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.